Clinical Milestones, Vector Innovation Key to Gene Therapy, GenoTher Biocluster's First International Summit,
PARIS--(BUSINESS WIRE)--Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), and its spin-off Atamyo Therapeutics made significant advances in their gene therapies for multiple rare diseases as highlighted in Genethon's most recent Newsletter.
Chief among them are key clinical milestones reached, including those reflected in Genethon's Phase 3 ready Duchene muscular dystrophy gene therapy (GNT0004); and Atamyo's significant milestones in clinical trials of gene therapies (ATA-100 and ATA-200) for treatment of two subtypes of limb-girdle muscular dystrophy (LGMD2I/R9 and LGMD2C/R5).
In addition, the GenoTher Biocluster, a public-private partnership serving as a leading ecosystem for generation of innovative genetic medicines' approaches, held its first international summit attended by 350 researchers, investors, biotech executives and public decision-makers representing more than 100 organizations.
In his CEO Commentary, Genethon's Frederic Revah discusses new research involving the organization's AAV platform to increase safety, efficacy and disease applications of gene therapies. Dr. Revah reports Genethon also is exploring non-viral based delivery systems, such as Lipid Nano Particles (LNPs), for their potential in gene editing.
Atamyo in April completed the dose escalation phase of a Phase 1b/2b trial in Europe of ATA-100 for LGMD2I/R9 and announced in June dosing in the US of the first two patients in a Phase 1b/2 study of ATA-200 for LGMD2C/R5. Both subtypes lead to loss of ambulation and other complications in children and there are no cures.
Read the full Newsletter to learn about these gene therapy advances and others.
About Genethon
As a pioneer in the discovery and development of gene therapies for rare diseases, Genethon is a non-profit laboratory that was established by AFM-Telethon. A first gene therapy for spinal muscular atrophy to which Genethon contributed has obtained a product license. With more than 200 scientists and professional staff, Genethon is pursuing its aim to develop therapies which change the lives of patients suffering from rare genetic diseases. Thirteen products stemming from Genethon's R&D or from collaborations are in clinical trial for diseases of the liver, blood, immune system, muscles and eyes. Seven other products could enter clinical trials over the next five years. More information at www.genethon.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Clinical Milestones, Vector Innovation Key to Gene Therapy, GenoTher Biocluster's First International Summit,
PARIS--(BUSINESS WIRE)--Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), and its spin-off Atamyo Therapeutics made significant advances in their gene therapies for multiple rare diseases as highlighted in Genethon's most recent Newsletter. Chief among them are key clinical milestones reached, including those reflected in Genethon's Phase 3 ready Duchene muscular dystrophy gene therapy (GNT0004); and Atamyo's significant milestones in clinical trials of gene therapies (ATA-100 and ATA-200) for treatment of two subtypes of limb-girdle muscular dystrophy (LGMD2I/R9 and LGMD2C/R5). In addition, the GenoTher Biocluster, a public-private partnership serving as a leading ecosystem for generation of innovative genetic medicines' approaches, held its first international summit attended by 350 researchers, investors, biotech executives and public decision-makers representing more than 100 organizations. In his CEO Commentary, Genethon's Frederic Revah discusses new research involving the organization's AAV platform to increase safety, efficacy and disease applications of gene therapies. Dr. Revah reports Genethon also is exploring non-viral based delivery systems, such as Lipid Nano Particles (LNPs), for their potential in gene editing. Atamyo in April completed the dose escalation phase of a Phase 1b/2b trial in Europe of ATA-100 for LGMD2I/R9 and announced in June dosing in the US of the first two patients in a Phase 1b/2 study of ATA-200 for LGMD2C/R5. Both subtypes lead to loss of ambulation and other complications in children and there are no cures. Read the full Newsletter to learn about these gene therapy advances and others. About Genethon As a pioneer in the discovery and development of gene therapies for rare diseases, Genethon is a non-profit laboratory that was established by AFM-Telethon. A first gene therapy for spinal muscular atrophy to which Genethon contributed has obtained a product license. With more than 200 scientists and professional staff, Genethon is pursuing its aim to develop therapies which change the lives of patients suffering from rare genetic diseases. Thirteen products stemming from Genethon's R&D or from collaborations are in clinical trial for diseases of the liver, blood, immune system, muscles and eyes. Seven other products could enter clinical trials over the next five years. More information at
CBS News
4 days ago
- CBS News
What is Alex's Lemonade Stand Foundation? Here's how you can join in fight against childhood cancer
Viewers of CBS News Philadelphia on TV, streaming and online have been hearing the name "Alex" for weeks in the buildup to our telethon on Wednesday, June 18, 2025. The telethon honors Alexandra "Alex" Scott, the namesake of the charity foundation, who was born on Jan. 18, 1996. Shortly before her first birthday, she was diagnosed with neuroblastoma, a type of cancer typically found in the adrenal glands that most commonly affects children. Alex faced many obstacles from that day forward, but she took them headfirst. On the day after her fourth birthday, she told her family she wanted to open a lemonade stand to raise money so doctors could "help other kids, like they helped me." Just a few months later, with the help of her brother, Alex held her first lemonade stand and raised $2,000. She continued the tradition yearly in her front yard until her passing in August 2004. Her legacy, however, lives on. Alex's story inspired children and their families around the world, leading to the creation of the Alex's Lemonade Stand Foundation to help with the fight against childhood cancer. Her efforts have created countless stories of hope from those suffering from childhood cancer, but also inspired those joining the fight. 19th Annual Alex Scott: A Stand for Hope Telethon CBS Philadelphia will present the 19th Annual Alex Scott: A Stand for Hope Telethon — a full day of fundraising for Alex's Lemonade Stand Foundation on Wednesday, live from CBS Philadelphia studios from 6 a.m. to 8 p.m. ET. At the CBS Philadelphia studios, our Great Hall will be transformed as we have an army of volunteers taking donations and honoring the memory of Alex Scott, the little girl who started it all. Alex's parents, Liz and Jay Scott, will also join us to spearhead the effort. Last year, CBS Philadelphia's 18th annual Alex Scott: A Stand For Hope Telethon raised a record-breaking $7.3 million for the fight against childhood cancer. A grand total of $7,309,976 was raised, which beat the previous record set in 2023 of $7.1 million. You can participate online, by phone call, text or Venmo all day long. The telethon is sponsored by Toyota and the Malvern School, which is part of the Busy Bees family. How to donate to the Alex Scott: A Stand for Hope Telethon CBS Philadelphia There are a variety of ways you can donate and join the fight against childhood cancer. Text 'CBSALEX' to 44321 Call 1-866-333-1213 Online: Venmo: @AlexsLemonadeStandFoundation (include CBS in the "What's it for" comment section) What is Alex's Lemonade Stand Foundation? Alex's Lemonade Stand Foundation is the largest independent charity dedicated to childhood cancer research and family support in the United States. The foundation changes the lives of children with cancer by funding impactful research, raising awareness, supporting families and empowering everyone to help cure childhood cancer. The Alex's Lemonade Stand Foundation Grant Program funds research every step of the way, from early-stage innovative research all the way through to lifesaving clinical trials for kids with cancer.
Yahoo
4 days ago
- Yahoo
/C O R R E C T I O N -- Human Longevity, Inc./
In the news release, Human Longevity, Inc. Expands Pancreatic Cancer Prevention Commitment with $1 Million Pledge for Qualified Members, issued 17-Jun-2025 by Human Longevity, Inc. over PR Newswire, we are advised by the company that the media contact information should be added to the public distribution. The complete, corrected release follows: SOUTH SAN FRANCISCO, Calif., June 17, 2025 /PRNewswire/ -- Human Longevity, Inc. (HLI), a global leader in precision medicine and proactive health, today announced an expansion of its $1 million pledge initiative—this time targeting late-stage pancreatic cancer. Building on the success of its recent prostate cancer commitment, HLI is advancing its mission to detect cancer earlier and improve outcomes for its members by offering financial and clinical support for those members diagnosed with late-stage pancreatic cancer while enrolled in its Executive Health and 100+ Longevity programs. Driving Innovation in Early Detection Through its Executive Health Program and 100+ Longevity Programs, Human Longevity has delivered care to over 10,000 members using a comprehensive platform that integrates whole genome sequencing, advanced imaging, and multiplex blood biomarker tracking. These efforts have enabled the development of what HLI believes to be one of the most advanced early detection algorithms for pancreatic cancer available today, including a new proprietary DNA-based pancreatic cancer screening test. In most cases, our multi-modal screening approach helps detect cancer at a stage when it is curable. But in the rare event that a member is diagnosed at a late stage, our $1 million pledge ensures they receive the most advanced care available—without the burden of financial barriers. How the $1 Million Pledge Works Eligible individuals must be active pledge participants in HLI's Executive Health Program or affiliated Longevity Programs for pancreatic cancer early screening. These programs include: Whole genome sequencing Whole-body MRI, with dedicated pancreatic imaging Long-term blood biomarker analysis A DNA-based pancreatic cancer screening blood test Qualified members diagnosed with late-stage pancreatic cancer while under HLI's care will receive up to $1 million toward treatment, care coordination, and access to a network of top-tier oncology experts from leading medical institutions. Transforming the Future of Pancreatic Cancer Care Pancreatic cancer is one of the deadliest forms of cancer due to its lack of early symptoms and late detection. Human Longevity's initiative aims to shift this paradigm by detecting disease earlier—when it is most treatable. The pledge not only offers support to individuals but also accelerates advancements in cancer screening technology through continuous real-world data integration and machine learning. About Human Longevity, Inc. Human Longevity, Inc. is a pioneering biotechnology company at the forefront of genomics, AI, and advanced medical technologies to extend healthspan and revolutionize preventative care. By leveraging vast genomic data, metabolomics, advanced imaging, and AI-driven diagnostics, Human Longevity is transforming healthcare from disease management to proactive prevention through its Executive Health and other Longevity Programs. The company remains committed to advancing medical research, improving patient outcomes, and unlocking the full potential of genomics to address the world's most pressing health challenges. Media Contactmedia@ View original content to download multimedia: SOURCE Human Longevity, Inc.
